Screening Methods for Anti-Ulcer Drugs

Screening Methods for Anti-Ulcer Drugs

1. Introduction & rationale for screening models

• Peptic ulcer disease (PUD) is a spectrum of mucosal disorders — gastric ulcers, duodenal ulcers (acute and chronic), and postoperative anastomotic ulcers — driven by an imbalance between aggressive factors (acid, pepsin, Helicobacter pylori) and mucosal defensive factors (mucus, bicarbonate, prostaglandins, blood flow) (SK Gupta Ch.35, p.527).
• The pharmacological targets validated in humans — H₂-receptor blockers, proton-pump (H⁺/K⁺-ATPase) inhibitors, cytoprotective prostaglandin analogues, antacids and mucosal protectives — define the mechanisms an ideal screen must be able to detect, so a battery of complementary models is used rather than a single assay (SK Gupta Ch.35, p.527).
• Persistently high morbidity and the continual arrival of newer chemical entities create an ongoing need for reproducible, mechanism-spanning preclinical screens before clinical testing (SK Gupta Ch.35, p.527).
• Requirements of an ideal experimental ulcer model (SK Gupta Ch.35, p.527):
  • Simple, reproducible, and allowing easy quantification of results.
  • Usable across a variety of animal species.
  • Inducing characteristic ulceration at specific, defined locations (stomach vs duodenum).
  • Operating through a defined and distinct mechanism of ulcerogenesis (so a panel covers acid-dependent, cytoprotection-dependent, neurogenic and ischaemic pathways).
  • Producing ulcers that do not spontaneously heal during the observation window.
  • Cost-effective and not unduly time-consuming.
• Two-tier screening philosophy — in-vitro mechanistic/target assays (receptor binding, enzyme inhibition) are used as the first, high-throughput filter; in-vivo whole-animal ulcer models then confirm efficacy, define the protective mechanism, and generate dose–response data (SK Gupta Ch.35, pp.527–536; Vogel V3 Part XI, p.2383).
• Parietal-cell physiology underpinning the screens — the gastric parietal cell is activated by three secretagogues, histamine (H₂), acetylcholine (M₃) and gastrin (CCK₂); gastrin and ACh also release histamine from enterochromaffin-like (ECL) cells, so histamine is the final common mediator of acid secretion. On stimulation, cytoplasmic tubulovesicles fuse into the apical secretory canaliculus where H⁺/K⁺-ATPase (the proton pump, exchanging intracellular H⁺ for luminal K⁺) effects the terminal step of acid output — the convergence point that makes the pump the most "downstream" screening target (Vogel V3 Part XI, p.2383; SK Gupta Ch.35, p.528).